biotech · Duchenne Muscular Dystrophy · Duchenne muscular dystrophy · SLDB
Solid Biosciences
Solid Biosciences clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 500 Rutherford Ave, Third Floor, Boston, Massachusetts 02129, US
- Founded
- 2013
- Employees
- 155
- Programs
- 16
- Drugs
- 20
- Patents
- 2
Solid Biosciences projects
7 ClinicalTrials.gov programs sponsored by Solid Biosciences.
Solid Biosciences has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Bevacizumab/Irinotecan
Solid Biosciences
Glioblastoma
1 trial -
Cetuximab
Solid Biosciences
Head and Neck Neoplasm
1 trial -
Erlotinib
Solid Biosciences
Leptomeningeal Carcinomatosis
1 trial -
SGT-001
Solid Biosciences
Duchenne Muscular Dystrophy
1 trial -
SGT-003-101
Solid Biosciences
Duchenne muscular dystrophy
1 trial -
docetaxel+CDDP
Solid Biosciences
Head and Neck Squamous Cell Carcinoma
1 trial -
genexolPM + cisplatin
Solid Biosciences
Locally Advanced Head and Neck Squamous Cell Carcinoma
1 trial
Frequently asked questions
How many clinical projects does Solid Biosciences have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.